Peer-reviewed veterinary case report
Pgp protein levels linked to shorter survival in dogs with lymphoma
By Vajdovich, Péter et al.·Published in Acta veterinaria Hungarica·2018·1 Department of Clinical Pathology and Oncology University of Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of Pgp (MDR1) immunohistochemistry in canine lymphoma - prognostic and clinical aspects.
- Species:
- dog
Plain-English summary
A group of dogs with multicentric lymphoma were treated with a combination of chemotherapy drugs, including cyclophosphamide and doxorubicin. Researchers looked at a protein called P-glycoprotein (Pgp) in their tumor cells to see if it could help predict how well the dogs would respond to treatment. They found that dogs with higher levels of Pgp had shorter survival times and were more likely to experience relapses. This suggests that measuring Pgp levels could help veterinarians determine the best treatment approach for dogs with lymphoma.
People also search for: dog lymphoma treatment · P-glycoprotein in dogs · chemotherapy side effects in dogs
Abstract
Permeability glycoprotein (P-glycoprotein, Pgp) immunohistochemistry (IHC) was evaluated in dogs with multicentric lymphoma treated with cyclophosphamide- doxorubicin-vincristine-prednisolone with or without L-Asparaginase. Lymph nodes of 33 untreated dogs were immunophenotyped: Ki67% and Pgp analyses (with anti-Pgp, monoclonal mouse C494 clone) were performed. Pgp positivity rate and intensity were determined microscopically (by manual counting done by two blinded authors in two parallel specimens). The median overall survival time (OST) was 333 days and the relapse-free period (RFP) 134 days. Pgp expressions were positive in 18 out of 33 (54.5%) of tumour cells. T-cell types stained more intensively. Lower OST and RFP were found with Pgp positivity ≥ 35% (OST: 240 days, RFP: 95 days) compared to Pgp positivity < 35% (OST: 428 days, RFP: 232 days). Intensive staining was associated with a lower OST and RFP (240 and 103 days, respectively) than weak staining (428 and 221 days, respectively). Death due to adverse drug reactions was best predicted at Pgp positivity ≤ 6.5% (sensitivity/specificity: 0.55/0.81) and ≤ 123 days (sensitivity/ specificity: 0.55/0.86). Pgp evaluation by IHC can have prognostic value with a properly established Pgp% positivity cut-off value in dogs treated with Pgp substrate drugs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29958524/